Abstract
The UK National Screening Committee recommended high-risk human papillomavirus (hrHPV) primary screening in 2016, and it was introduced in England 3 years later, to increase the test sensitivity for cervical intraepithelial neoplasia, reducing the risk of developing cervical cancer. The 2018 call by the World Health Organization to eliminate cervical cancer as a public health measure supports primary HPV screening as both clinically effective and cost effective. In this commentary, we review the emerging evidence from primary HPV screening as pilot and replacement programmes establish themselves globally.
Original language | English |
---|---|
Pages (from-to) | 131-134 |
Number of pages | 1 |
Journal | BJOG: An International Journal of Obstetrics Gynaecology |
Volume | 130 |
Issue number | 2 |
Early online date | 6 Oct 2022 |
DOIs |
|
Publication status | Published - Jan 2023 |